Amicus Net Receivables from 2010 to 2026
| FOLD Stock | USD 14.31 0.01 0.07% |
Net Receivables | First Reported 2011-03-31 | Previous Quarter 105.8 M | Current Value 113.8 M | Quarterly Volatility 34 M |
Check Amicus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amicus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.3 M, Interest Expense of 59.9 M or Other Operating Expenses of 607.9 M, as well as many indicators such as Price To Sales Ratio of 5.93, Dividend Yield of 0.0 or PTB Ratio of 13.96. Amicus financial statements analysis is a perfect complement when working with Amicus Therapeutics Valuation or Volatility modules.
Amicus | Net Receivables | Build AI portfolio with Amicus Stock |
Analyzing Amicus Therapeutics's Net Receivables over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Receivables has evolved provides context for assessing Amicus Therapeutics's current valuation and future prospects.
Latest Amicus Therapeutics' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Amicus Therapeutics over the last few years. It is Amicus Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amicus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Amicus Net Receivables Regression Statistics
| Arithmetic Mean | 39,757,582 | |
| Geometric Mean | 13,930,882 | |
| Coefficient Of Variation | 109.92 | |
| Mean Deviation | 37,007,038 | |
| Median | 21,962,000 | |
| Standard Deviation | 43,699,564 | |
| Sample Variance | 1909.7T | |
| Range | 121M | |
| R-Value | 0.92 | |
| Mean Square Error | 296.7T | |
| R-Squared | 0.85 | |
| Slope | 7,998,866 | |
| Total Sum of Squares | 30554.4T |
Amicus Net Receivables History
About Amicus Therapeutics Financial Statements
Amicus Therapeutics stakeholders use historical fundamental indicators, such as Amicus Therapeutics' Net Receivables, to determine how well the company is positioned to perform in the future. Although Amicus Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amicus Therapeutics' assets and liabilities are reflected in the revenues and expenses on Amicus Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amicus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 116.3 M | 122.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:Check out the analysis of Amicus Therapeutics Correlation against competitors. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Will Biotechnology sector continue expanding? Could Amicus diversify its offerings? Factors like these will boost the valuation of Amicus Therapeutics. Market participants price Amicus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Amicus Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.04) | Revenue Per Share | Quarterly Revenue Growth 0.195 | Return On Assets | Return On Equity |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Amicus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.